{"id":"etomidate","rwe":[],"_fda":{"id":"0635683b-880b-0cd4-e063-6394a90ab73e","set_id":"0635683b-880a-0cd4-e063-6394a90ab73e","openfda":{"nui":["N0000175975","N0000175681"],"unii":["Z22628B598"],"route":["INTRAVENOUS"],"rxcui":["1654006"],"spl_id":["0635683b-880b-0cd4-e063-6394a90ab73e"],"brand_name":["ETOMIDATE injection, solution"],"spl_set_id":["0635683b-880a-0cd4-e063-6394a90ab73e"],"package_ndc":["51662-1634-1"],"product_ndc":["51662-1634"],"generic_name":["ETOMIDATE INJECTION, SOLUTION"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["General Anesthesia [PE]"],"substance_name":["ETOMIDATE"],"pharm_class_epc":["General Anesthetic [EPC]"],"manufacturer_name":["HF Acquisition Co LLC, DBA HealthFirst"],"application_number":["ANDA206126"],"original_packager_product_ndc":["55150-222"]},"version":"1","warnings":["WARNINGS INTRAVENOUS ETOMIDATE SHOULD BE ADMINISTERED ONLY BY PERSONS TRAINED IN THE ADMINISTRATION OF GENERAL ANESTHETICS AND IN THE MANAGEMENT OF COMPLICATIONS ENCOUNTERED DURING THE CONDUCT OF GENERAL ANESTHESIA. BECAUSE OF THE HAZARDS OF PROLONGED SUPPRESSION OF ENDOGENOUS CORTISOL AND ALDOSTERONE PRODUCTION, THIS FORMULATION IS NOT INTENDED FOR ADMINISTRATION BY PROLONGED INFUSION. Pediatric Neurotoxicity: Published animal studies demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity increase neuronal apoptosis in the developing brain and result in long-term cognitive deficits when used for longer than 3 hours. The clinical significance of these findings is not clear. However, based on the available data, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately three years of age in humans (see PRECAUTIONS/PREGNANCY , PEDIATRIC USE , ANIMAL TOXICOLOGY AND/OR PHARMACOLOGY ). Some published studies in children suggest that similar deficits may occur after repeated or prolonged exposures to anesthetic agents early in life and may result in adverse cognitive or behavioral effects. These studies have substantial limitations, and it is not clear if the observed effects are due to the anesthetic/sedation drug administration or other factors such as the surgery or underlying illness. Anesthetic and sedation drugs are a necessary part of the care of children needing surgery, other procedures, or tests that cannot be delayed, and no specific medications have been shown to be safer than any other. Decisions regarding the timing of any elective procedures requiring anesthesia should take into consideration the benefits of the procedure weighed against the potential risks."],"overdosage":["OVERDOSAGE Overdosage may occur from too rapid or repeated injections. Too rapid injection may be followed by a fall in blood pressure. No adverse cardiovascular or respiratory effects attributable to etomidate overdose have been reported. In the event of suspected or apparent overdosage, the drug should be discontinued, a patent airway established (intubate, if necessary) or maintained and oxygen administered with assisted ventilation, if necessary."],"description":["DESCRIPTION Etomidate Injection, USP is a sterile, non-pyrogenic, clear, colorless solution, free from visible particles. Each milliliter contains etomidate USP 2 mg, propylene glycol 35% v/v. The pH is 6.0 (4.0 to 7.0). It is intended for the induction of general anesthesia by intravenous injection. The drug etomidate is chemically identified as (R)-(+)-ethyl-1-(1-phenylethyl)-1H-imidazole-5-carboxylate and has the following structural formula: Structure"],"precautions":["PRECAUTIONS Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenesis Long-term animal studies to evaluate the carcinogenic potential of etomidate have not been completed. Mutagenesis Studies to evaluate the mutagenic potential of etomidate have not been completed. Impairment of Fertility In a fertility and early embryonic development study in which male and female rats were treated intravenously with 0.31, 1.25, and 5 mg/kg/day etomidate (0.17, 0.68, and 2.7 times the human induction dose of 0.3 mg/kg based on body surface area) prior to mating, no adverse effects on fertility were noted. Pregnancy Risk Summary There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, fetal deaths and reduced pup survival were noted after intravenous administration of etomidate to pregnant rats at doses 0.17 times the human induction dose of 0.3 mg/kg. Reduced pup survival was noted after intravenous administration of etomidate to pregnant rabbits at 1.6 times the human induction dose. Published studies in pregnant primates demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity during the period of peak brain development increases neuronal apoptosis in the developing brain of the offspring when used for longer than 3 hours. There are no data on pregnancy exposures in primates corresponding to periods prior to the third trimester in humans. [See Data] The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data No malformations or adverse fetal effects were noted in a study in which pregnant rats were intravenously administered 0.31, 1.25, or 5 mg/kg/day etomidate (0.17, 0.68, or 2.7 times the human induction dose of 0.3 mg/kg based on body surface area) during organogenesis (Gestation Days 6 to 15). Reduced pup survival was noted in all doses tested in a study in which pregnant rabbits were intravenously administered 1.5 or 4.5 mg/kg/day etomidate (1.6 or 4.9 times the human induction dose of 0.3 mg/kg based on body surface area) during organogenesis (Gestation Day 6 to 18). These doses also produced maternal toxicity (increased mortality). Increased still born fetuses and decreased pup survival was noted at all doses tested in a study where pregnant rats were intravenously administered 0.31, 1.25, or 5 mg/kg/day etomidate (0.17, 0.68, or 2.7 times the human induction dose of 0.3 mg/kg based on body surface area) during gestation and throughout lactation (Gestation Day 16 through Lactation Day 21). These doses also produced maternal toxicity (decreased food consumption and increased mortality). In this study, offspring were not evaluated for sexual maturation, neurobehavioral function including learning and memory, or reproductive function. In a published study in primates, administration of an anesthetic dose of ketamine for 24 hours on Gestation Day 122 increased neuronal apoptosis in the developing brain of the fetus. In other published studies, administration of either isoflurane or propofol for 5 hours on Gestation Day 120 resulted in increased neuronal and oligodendrocyte apoptosis in the developing brain of the offspring. With respect to brain development, this time period corresponds to the third trimester of gestation in the human. The clinical significance of these findings is not clear; however, studies in juvenile animals suggest neuroapoptosis correlates with long-term cognitive deficits (See WARNINGS/PEDIATRIC NEUROTOXICITY , PRECAUTIONS/PREGNANCY , ANIMAL TOXICOLOGY AND/OR PHARMACOLOGY ). Labor and Delivery There are insufficient data to support use of intravenous etomidate in obstetrics, including Caesarean section deliveries. Therefore, such use is not recommended. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when etomidate is administered to a nursing mother. Pediatric Use There are inadequate data for etomidate to make dosage recommendations for induction of anesthesia in patients below the age of ten (10) years; therefore, such use is not recommended (see also DOSAGE AND ADMINISTRATION ). Published juvenile animal studies demonstrate that the administration of anesthetic and sedation drugs, such as etomidate, that either block NMDA receptors or potentiate the activity of GABA during the period of rapid brain growth or synaptogenesis, results in widespread neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis. Based on comparisons across species, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately 3 years of age in humans. In primates, exposure to 3 hours of ketamine that produced a light surgical plane of anesthesia did not increase neuronal cell loss, however, treatment regimens of 5 hours or longer of isoflurane increased neuronal cell loss. Data from isoflurane-treated rodents and ketamine-treated primates suggest that the neuronal and oligodendrocyte cell losses are associated with prolonged cognitive deficits in learning and memory. The clinical significance of these nonclinical findings is not known, and healthcare providers should balance the benefits of appropriate anesthesia in pregnant women, neonates, and young children who require procedures with the potential risks suggested by the nonclinical data. (See WARNINGS/PEDIATRIC NEUROTOXICITY , PRECAUTIONS/PREGNANCY , and ANIMAL TOXICOLOGY AND/OR PHARMACOLOGY ). Geriatric Use: Clinical data indicates that etomidate may induce cardiac depression in elderly patients, particularly those with hypertension (see CLINICAL PHARMACOLOGY and OTHER ADVERSE OBSERVATIONS , CIRCULATORY SYSTEM ). Elderly patients may require lower doses of etomidate than younger patients. Age-related differences in pharmacokinetic parameters have been observed in clinical studies (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION ). This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. Plasma Cortisol Levels: Induction doses of etomidate have been associated with reduction in plasma cortisol and aldosterone concentrations (see CLINICAL PHARMACOLOGY ). These have not been associated with changes in vital signs or evidence of increased mortality; however, where concern exists for patients undergoing severe stress, exogenous replacement should be considered. Information for Patients: Effect of anesthetic and sedation drugs on early brain development Studies conducted in young animals and children suggest repeated or prolonged use of general anesthetic or sedation drugs in children younger than 3 years may have negative effects on their developing brains. Discuss with parents and caregivers the benefits, risks, and timing and duration of surgery or procedures requiring anesthetic and sedation drugs. (See WARNINGS/PEDIATRIC NEUROTOXICITY )."],"how_supplied":["HOW SUPPLIED Etomidate Injection, USP is a sterile, non-pyrogenic, clear, colorless solution, free from visible particles and is supplied as follows: 20 mg per 10 mL (2 mg / mL) 10 mL Single-Dose Vials in a Carton of 10 NDC 51662-1634-1 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. The vial stoppers are not made with natural rubber latex."],"effective_time":"20230925","adverse_reactions":["ADVERSE REACTIONS The most frequent adverse reactions associated with use of intravenous etomidate are transient venous pain on injection and transient skeletal muscle movements, including myoclonus: 1. Transient venous pain was observed immediately following intravenous injection of etomidate in about 20% of the patients, with considerable difference in the reported incidence (1.2% to 42%). This pain is usually described as mild to moderate in severity but it is occasionally judged disturbing. The observation of venous pain is not associated with a more than usual incidence of thrombosis or thrombophlebitis at the injection site. Pain also appears to be less frequently noted when larger, more proximal arm veins are employed and it appears to be more frequently noted when smaller, more distal, hand or wrist veins are employed. 2. Transient skeletal muscle movements were noted following use of intravenous etomidate in about 32% of the patients, with considerable difference in the reported incidence (22.7% to 63%). Most of these observations were judged mild to moderate in severity but some were judged disturbing. The incidence of disturbing movements was less when 0.1 mg of fentanyl was given immediately before induction. These movements have been classified as myoclonic in the majority of cases (74%), but averting movements (7%), tonic movements (10%), and eye movements (9%) have also been reported. No exact classification is available, but these movements may also be placed into three groups by location: a. Most movements are bilateral. The arms, legs, shoulders, neck, chest wall, trunk and all four extremities have been described in some cases, with one or more of these muscle groups predominating in each individual case. Results of electroencephalographic studies suggest that these muscle movements are a manifestation of disinhibition of cortical activity; cortical electroencephalograms, taken during periods when these muscle movements were observed, have failed to reveal seizure activity. b. Other movements are described as either unilateral or having a predominance of activity of one side over the other. These movements sometimes resemble a localized response to some stimuli, such as venous pain on injection, in the lightly anesthetized patient (averting movements). Any muscle group or groups may be involved, but a predominance of movement of the arm in which the intravenous infusion is started is frequently noted. c. Still other movements probably represent a mixture of the first two types. Skeletal muscle movements appear to be more frequent in patients who also manifest venous pain on injection. Other Adverse Observations Respiratory System: Hyperventilation, hypoventilation, apnea of short duration (5 to 90 seconds with spontaneous recovery); laryngospasm, hiccup and snoring suggestive of partial upper airway obstruction have been observed in some patients. These conditions were managed by conventional countermeasures. Circulatory System: Hypertension, hypotension, tachycardia, bradycardia and other arrhythmias have occasionally been observed during induction and maintenance of anesthesia. One case of severe hypotension and tachycardia, judged to be anaphylactoid in character, has been reported. Geriatric patients, particularly those with hypertension, may be at increased risk for the development of cardiac depression following etomidate administration (see CLINICAL PHARMACOLOGY ). Gastrointestinal System: Postoperative nausea and/or vomiting following induction of anesthesia with etomidate is probably no more frequent than the general incidence. When etomidate was used for both induction and maintenance of anesthesia in short procedures such as dilation and curettage, or when insufficient analgesia was provided, the incidence of postoperative nausea and/or vomiting was higher than that noted in control patients who received thiopental."],"contraindications":["CONTRAINDICATIONS Etomidate is contraindicated in patients who have shown hypersensitivity to it."],"recent_major_changes":[""],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Etomidate is a general anesthetic without analgesic activity. Intravenous injection of etomidate produces anesthesia characterized by a rapid onset of action, usually within one minute. Duration of anesthesia is dose dependent but relatively brief, usually three to five minutes when an average dose of 0.3 mg/kg is employed. Immediate recovery from anesthesia (as assessed by awakening time, time needed to follow simple commands and time to perform simple tests after anesthesia as well as they were performed before anesthesia), based upon data derived from short operative procedures where intravenous etomidate was used for both induction and maintenance of anesthesia, is about as rapid as, or slightly faster than, immediate recovery after similar use of thiopental. These same data revealed that the immediate recovery period will usually be shortened in adult patients by the intravenous administration of approximately 0.1 mg of intravenous fentanyl, one or two minutes before induction of anesthesia, probably because less etomidate is generally required under these circumstances (consult the package insert for fentanyl before using). The most characteristic effect of intravenous etomidate on the respiratory system is a slight elevation in arterial carbon dioxide tension (PaCO2) (see ADVERSE REACTIONS ). Reduced cortisol plasma levels have been reported with induction doses of 0.3 mg/kg etomidate. These persist for approximately 6 to 8 hours and appear to be unresponsive to ACTH administration. The intravenous administration of up to 0.6 mg/kg of etomidate to patients with severe cardiovascular disease has little or no effect on myocardial metabolism, cardiac output, peripheral circulation or pulmonary circulation. The hemodynamic effects of etomidate have in most cases been qualitatively similar to those of thiopental sodium, except that the heart rate tended to increase by a moderate amount following administration of thiopental under conditions where there was little or no change in heart rate following administration of etomidate. However, clinical data indicates that etomidate administration in geriatric patients, particularly those with hypertension, may result in decreases in heart rate, cardiac index, and mean arterial blood pressure. There are insufficient data concerning use of etomidate in patients with recent severe trauma or hypovolemia to predict cardiovascular response under such circumstances. Clinical experience and special studies to date suggest that standard doses of intravenous etomidate ordinarily neither elevate plasma histamine nor cause signs of histamine release. Limited clinical experience, as well as animal studies, suggests that inadvertent intra-arterial injection of etomidate, unlike thiobarbiturates, will not usually be followed by necrosis of tissue distal to the injection site. Intra-arterial injection of etomidate is, however, not recommended. Etomidate induction is associated with a transient 20% to 30% decrease in cerebral blood flow. This reduction in blood flow appears to be uniform in the absence of intracranial space occupying lesions. As with other intravenous induction agents, reduction in cerebral oxygen utilization is roughly proportional to the reduction in cerebral blood flow. In patients with and without intracranial space occupying lesions, etomidate induction is usually followed by a moderate lowering of intracranial pressure, lasting several minutes. All of these studies provided for avoidance of hypercapnia. Information concerning regional cerebral perfusion in patients with intracranial space occupying lesions is too limited to permit definitive conclusions. Preliminary data suggests that etomidate will usually lower intraocular pressure moderately. Etomidate is rapidly metabolized in the liver. Minimal anesthetic plasma levels of unchanged drug are equal to or higher than 0.23 mcg/mL; they decrease rapidly up to 30 minutes following injection and thereafter more slowly with a half-life value of about 75 minutes. Approximately 75% of the administered dose is excreted in the urine during the first day after injection. The chief metabolite is R-(+)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid, resulting from hydrolysis of etomidate, and accounts for about 80% of the urinary excretion. Limited pharmacokinetic data in patients with cirrhosis and esophageal varices suggest that the volume of distribution and elimination half-life of etomidate are approximately double that seen in healthy subjects. In clinical studies, elderly patients demonstrated decreased initial distribution volumes and total clearance of etomidate. Protein binding of etomidate to serum albumin was also significantly decreased in these individuals. Reduced plasma cortisol and aldosterone levels have been reported following induction doses of etomidate. These results persist for approximately 6 to 8 hours and appear to be unresponsive to ACTH stimulation. This probably represents blockage of 11 beta-hydroxylation within the adrenal cortex."],"indications_and_usage":["INDICATIONS & USAGE SECTION Etomidate Injection is indicated by intravenous injection for the induction of general anesthesia. When considering use of Etomidate Injection, the usefulness of its hemodynamic properties (see CLINICAL PHARMACOLOGY ) should be weighed against the high frequency of transient skeletal muscle movements (see ADVERSE REACTIONS ). Intravenous Etomidate Injection is also indicated for the supplementation of subpotent anesthetic agents, such as nitrous oxide in oxygen, during maintenance of anesthesia for short operative procedures such as dilation and curettage or cervical conization."],"dosage_and_administration":["DOSAGE AND ADMINISTATION Do not administer unless solution is clear and container is undamaged. Discard unused portion (see DOSAGE AND ADMINISTRATION ). Etomidate Injection is intended for administration only by the intravenous route (see CLINICAL PHARMACOLOGY ). The dose for induction of anesthesia in adult patients and in pediatric patients above the age of ten (10) years will vary between 0.2 mg/kg and 0.6 mg/kg of body weight, and it must be individualized in each case. The usual dose for induction in these patients is 0.3 mg/kg, injected over a period of 30 to 60 seconds. There are inadequate data to make dosage recommendations for induction of anesthesia in patients below the age of ten (10) years; therefore, such use is not recommended. Geriatric patients may require reduced doses of etomidate. Smaller increments of intravenous etomidate may be administered to adult patients during short operative procedures to supplement subpotent anesthetic agents, such as nitrous oxide. The dosage employed under these circumstances, although usually smaller than the original induction dose, must be individualized. There are insufficient data to support this use of etomidate for longer adult procedures or for any procedures in pediatric patients; therefore, such use is not recommended. The use of intravenous fentanyl and other neuroactive drugs employed during the conduct of anesthesia may alter the etomidate dosage requirements. Consult the prescribing information for all other such drugs before using. Premedication: Etomidate Injection is compatible with commonly administered pre-anesthetic medications, which may be employed as indicated. See also CLINICAL PHARMACOLOGY , ADVERSE REACTIONS , and dosage recommendations for maintenance of anesthesia. Etomidate Injection anesthesia does not significantly alter the usual dosage requirements of neuromuscular blocking agents employed for endotracheal intubation or other purposes shortly after induction of anesthesia. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. To prevent needle-stick injuries, needles should not be recapped, purposely bent, or broken by hand."],"spl_product_data_elements":["ETOMIDATE injection, solution ETOMIDATE injection, solution WATER ETOMIDATE ETOMIDATE PROPYLENE GLYCOL"],"animal_pharmacology_and_or_toxicology":["ANIMAL TOXICOLOGY AND/OR PHARMACOLOGY Published studies in animals demonstrate that the use of anesthetic agents during the period of rapid brain growth or synaptogenesis results in widespread neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis. Based on comparisons across species, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester through the first several months of life, but may extend out to approximately 3 years of age in humans. In primates, exposure to 3 hours of an anesthetic regimen that produced a light surgical plane of anesthesia did not increase neuronal cell loss, however, treatment regimens of 5 hours or longer increased neuronal cell loss. Data in rodents and in primates suggest that the neuronal and oligodendrocyte cell losses are associated with subtle but prolonged cognitive deficits in learning and memory. The clinical significance of these nonclinical findings is not known, and healthcare providers should balance the benefits of appropriate anesthesia in neonates and young children who require procedures against the potential risks suggested by the nonclinical data (See WARNINGS/PEDIATRIC NEUROTOXICITY , PRECAUTIONS/PREGNANCY , PEDIATRIC USE ). DISTRIBUTED BY: HF ACQUISITION CO LLC, DBA HEALTHFIRST 11629 49TH PL W MUKILTEO, WA 98275 Manufactured by: Eugia Pharma Specialities Limited Hyderabad - 500032 India"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL, CONTAINER LABEL MFG CONTAINER LABEL MFG CONTAINER LABEL","PRINCIPAL DISPLAY PANEL, SERIALIZED LABEL 51662-1634-1 SERIALIZED LABEL SERIALIZED LABEL"]},"tags":[{"label":"General Anesthetic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 11B2, mitochondrial","category":"target"},{"label":"CYP11B2","category":"gene"},{"label":"CYP11B1","category":"gene"},{"label":"GABRA2","category":"gene"},{"label":"N01AX07","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"General anesthesia","category":"indication"},{"label":"Hospira","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Anesthetics","category":"pharmacology"},{"label":"Anesthetics, Intravenous","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Hypnotics and Sedatives","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":192.869,"date":"","count":64,"signal":"Fear","source":"DrugCentral FAERS","actionTaken":"Reported 64 times (LLR=193)"},{"llr":172.843,"date":"","count":58,"signal":"Renal injury","source":"DrugCentral FAERS","actionTaken":"Reported 58 times (LLR=173)"},{"llr":168.429,"date":"","count":65,"signal":"Anaphylactic shock","source":"DrugCentral FAERS","actionTaken":"Reported 65 times (LLR=168)"},{"llr":161.635,"date":"","count":92,"signal":"Multiple organ dysfunction syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 92 times (LLR=162)"},{"llr":150.98,"date":"","count":99,"signal":"Cardiac arrest","source":"DrugCentral FAERS","actionTaken":"Reported 99 times (LLR=151)"},{"llr":149.672,"date":"","count":62,"signal":"Emotional distress","source":"DrugCentral FAERS","actionTaken":"Reported 62 times (LLR=150)"},{"llr":144.249,"date":"","count":47,"signal":"Anhedonia","source":"DrugCentral FAERS","actionTaken":"Reported 47 times (LLR=144)"},{"llr":119.835,"date":"","count":97,"signal":"Renal failure","source":"DrugCentral FAERS","actionTaken":"Reported 97 times (LLR=120)"},{"llr":119,"date":"","count":67,"signal":"Injury","source":"DrugCentral FAERS","actionTaken":"Reported 67 times (LLR=119)"},{"llr":106.171,"date":"","count":59,"signal":"Unevaluable event","source":"DrugCentral FAERS","actionTaken":"Reported 59 times (LLR=106)"},{"llr":101.074,"date":"","count":71,"signal":"Bradycardia","source":"DrugCentral FAERS","actionTaken":"Reported 71 times (LLR=101)"},{"llr":89.985,"date":"","count":113,"signal":"Hypotension","source":"DrugCentral FAERS","actionTaken":"Reported 113 times (LLR=90)"},{"llr":88.139,"date":"","count":44,"signal":"Serotonin syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 44 times (LLR=88)"},{"llr":87.32,"date":"","count":22,"signal":"Hyperthermia malignant","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=87)"},{"llr":68.659,"date":"","count":62,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 62 times (LLR=69)"}],"commonSideEffects":[{"effect":"Transient skeletal muscle movements","drugRate":"32%","severity":"common","_validated":true},{"effect":"Transient venous pain","drugRate":"20%","severity":"common","_validated":true},{"effect":"Hyperventilation","drugRate":"reported","severity":"unknown"},{"effect":"Hypoventilation","drugRate":"reported","severity":"unknown"},{"effect":"Apnea","drugRate":"reported","severity":"unknown"},{"effect":"Laryngospasm","drugRate":"reported","severity":"unknown"},{"effect":"Hiccup","drugRate":"reported","severity":"unknown"},{"effect":"Snoring","drugRate":"reported","severity":"unknown"},{"effect":"Hypertension","drugRate":"reported","severity":"unknown"},{"effect":"Hypotension","drugRate":"reported","severity":"unknown"},{"effect":"Tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"Bradycardia","drugRate":"reported","severity":"unknown"},{"effect":"Arrhythmias","drugRate":"reported","severity":"unknown"},{"effect":"Postoperative nausea","drugRate":"reported","severity":"unknown"},{"effect":"Postoperative vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Thrombosis","drugRate":"reported","severity":"unknown"},{"effect":"Thrombophlebitis","drugRate":"reported","severity":"unknown"},{"effect":"Myoclonus","drugRate":"reported","severity":"unknown"},{"effect":"Averting movements","drugRate":"reported","severity":"unknown"},{"effect":"Tonic movements","drugRate":"reported","severity":"unknown"},{"effect":"Eye movements","drugRate":"reported","severity":"unknown"}],"contraindications":["Adrenal cortical hypofunction","Low blood pressure"],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, fetal deaths and reduced pup survival were noted after intravenous administration of etomidate to pregnant rats at doses 0.17 times the human induction dose of 0.3 mg/kg. Reduced pup survival was noted after intravenous administration of etomidate to pregnant rabbits at 1.6 times the human induction dose. Published studies in pregnant primates demonstrate that the administration of anesthetic and sedation drugs, such as etomidate, that either block NMDA receptors or potentiate the activity of GABA during the period of rapid brain growth or synaptogenesis, results in widespread neuronal an","Geriatric use":"Clinical data indicates that etomidate may induce cardiac depression in elderly patients, particularly those with hypertension (see CLINICAL PHARMACOLOGY and OTHER ADVERSE OBSERVATIONS, Circulatory System).Elderly patients may require lower doses of etomidate than younger patients. Age-related differences in pharmacokinetic parameters have been observed in clinical studies (see CLINACOLOGY and DOSAGE AND ADMINISTRATION).This drug is known to be substantially excreted by ","Paediatric use":"There are inadequate data to make dosage recommendations for induction of anesthesia in patients below the age of ten (10) years; therefore, such use is not recommended (see DOSAGE AND ADMINISTRATION). Published juvenile animal studies demonstrate that the administration of anesthetic and sedation drugs, such as etomidate, that either block NMDA receptors or potentiate the activity of GABA during the period of rapid brain growth or synaptogenesis, results in widespread neuronal an"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ETOMIDATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:05:05.063331+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:05:10.211160+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ETOMIDATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:05:10.500777+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:05:03.960016+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:05:03.960054+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:05:03.960059+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: GABA-A receptor; anion channel positive modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:05:11.591517+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL681/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:05:11.226601+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA206126","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:05:03.960062+00:00"}},"allNames":"amidate","offLabel":[],"synonyms":["etomidate","(+)-Etomidate","amidate","D-Etomidate","hypnomidate"],"timeline":[{"date":"1982-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from HOSPIRA to Hospira"},{"date":"1982-09-07","type":"positive","source":"DrugCentral","milestone":"FDA approval (Hospira)"},{"date":"2017-04-18","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 9 manufacturers approved"}],"approvals":[{"date":"1982-09-07","orphan":false,"company":"HOSPIRA","regulator":"FDA"}],"brandName":"Amidate","ecosystem":[{"indication":"General anesthesia","otherDrugs":[{"name":"acetylcysteine","slug":"acetylcysteine","company":"Apothecon"},{"name":"alfentanil","slug":"alfentanil","company":"Akorn"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"amobarbital","slug":"amobarbital","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Cytochrome P450 11B2, mitochondrial","novelty":"Follow-on","targets":[{"gene":"CYP11B2","source":"DrugCentral","target":"Cytochrome P450 11B2, mitochondrial","protein":"Cytochrome P450 11B2, mitochondrial"},{"gene":"CYP11B1","source":"DrugCentral","target":"Cytochrome P450 11B1, mitochondrial","protein":"Cytochrome P450 11B1, mitochondrial"},{"gene":"GABRA2","source":"DrugCentral","target":"GABA A receptor alpha-2/beta-2/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-2"},{"gene":"GABRB2","source":"DrugCentral","target":"GABA A receptor alpha-2/beta-2/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit beta-2"},{"gene":"GABRG2","source":"DrugCentral","target":"GABA A receptor alpha-2/beta-2/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit gamma-2"},{"gene":"GABRA1","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-2/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-1"}],"modality":"Small Molecule","drugClass":"General Anesthetic [EPC]","explanation":"","oneSentence":"","technicalDetail":"Amidate (etomidate) is a non-barbiturate, imidazole-derived general anesthetic that selectively inhibits the mitochondrial enzyme cytochrome P450 11B2 (11β-HSD1), which is involved in the conversion of cortisone to cortisol, thereby reducing cortisol levels and inducing sedation."},"commercial":{"launchDate":"1982","_launchSource":"DrugCentral (FDA 1982-09-07, HOSPIRA)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1109","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ETOMIDATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ETOMIDATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:29:16.379772","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:05:14.072359+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ketamine","drugSlug":"ketamine","fdaApproval":"1970-02-19","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"propofol","drugSlug":"propofol","fdaApproval":"1989-10-02","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sodium oxybate","drugSlug":"sodium-oxybate","fdaApproval":"2002-07-17","patentExpiry":"Sep 15, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nitrous oxide","drugSlug":"nitrous-oxide","fdaApproval":"","relationship":"same-class"},{"drugName":"esketamine","drugSlug":"esketamine","fdaApproval":"2019-05-03","patentExpiry":"Sep 10, 2035","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"etomidate","indications":{"approved":[{"name":"General anesthesia","source":"DrugCentral","snomedId":50697003,"regulator":"FDA","eligibility":"No specific patient eligibility criteria mentioned, but the usefulness of its hemodynamic properties should be weighed against the high frequency of transient skeletal muscle movements."}],"offLabel":[],"pipeline":[]},"currentOwner":"Hospira","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"ketamine","brandName":"ketamine","genericName":"ketamine","approvalYear":"1970","relationship":"same-class"},{"drugId":"propofol","brandName":"propofol","genericName":"propofol","approvalYear":"1989","relationship":"same-class"},{"drugId":"sodium-oxybate","brandName":"sodium oxybate","genericName":"sodium oxybate","approvalYear":"2002","relationship":"same-class"},{"drugId":"nitrous-oxide","brandName":"nitrous oxide","genericName":"nitrous oxide","approvalYear":"","relationship":"same-class"},{"drugId":"esketamine","brandName":"esketamine","genericName":"esketamine","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07491991","phase":"PHASE4","title":"Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery","status":"COMPLETED","sponsor":"Qianfoshan Hospital","startDate":"2025-03-02","conditions":["Postoperative Pain","NEBULIZATION","Thyroid Surgery"],"enrollment":96,"completionDate":"2026-03-01"},{"nctId":"NCT05277896","phase":"PHASE4","title":"Randomized Trial of Sedative Choice for Intubation","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-06","conditions":["Acute Respiratory Failure"],"enrollment":2367,"completionDate":"2025-09-06"},{"nctId":"NCT07474545","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Hunan Kelun Pharmaceutical Co., Ltd.","startDate":"2026-03-07","conditions":["Healthy Volunteers"],"enrollment":76,"completionDate":"2027-12-31"},{"nctId":"NCT07460310","phase":"NA","title":"Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":["Ankle Sprain","Ankle (Ligaments); Instability (Old Injury)","Pain Management","ERAS","Ankle Arthroscopy"],"enrollment":200,"completionDate":"2026-12-30"},{"nctId":"NCT07222007","phase":"","title":"Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients","status":"RECRUITING","sponsor":"Zeliha Alicikus","startDate":"2026-02-18","conditions":["Critically Ill","Intubation Complication","Oxygenation","Airway Management","Propofol","Ketamine"],"enrollment":4,"completionDate":"2026-07-01"},{"nctId":"NCT04871308","phase":"NA","title":"Dexmedetomidine and Myocardial Protection","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2021-07-07","conditions":["Cardiac Surgery","Cardiopulmonary Bypass"],"enrollment":224,"completionDate":"2025-01-07"},{"nctId":"NCT05358535","phase":"PHASE3","title":"Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-09-19","conditions":["Anesthesia","Propofol Adverse Reaction","Etomidate Adverse Reaction","Anesthesia Complication","Anesthesia; Adverse Effect","Anesthesia; Reaction"],"enrollment":200,"completionDate":"2027-03"},{"nctId":"NCT07271849","phase":"PHASE4","title":"Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients","status":"RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-10-28","conditions":["Postoperative Pain, Acute","Hemodynamics","Total Knee Arthroplasty (TKA)"],"enrollment":162,"completionDate":"2026-10-31"},{"nctId":"NCT03263117","phase":"PHASE4","title":"SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-07-01","conditions":["Stroke"],"enrollment":260,"completionDate":"2023-04-22"},{"nctId":"NCT07235514","phase":"NA","title":"Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-12-01","conditions":["Ischemic Stroke","Anterior Cerebral Circulation","General Anesthesia","Procedural Sedation","Thrombectomy"],"enrollment":958,"completionDate":"2029-03-01"},{"nctId":"NCT07045467","phase":"PHASE1","title":"Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study","status":"RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-07-01","conditions":["Chronic Kidney Diseases","Renal Transplantation"],"enrollment":30,"completionDate":"2027-06-01"},{"nctId":"NCT07089173","phase":"NA","title":"The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Study","status":"RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-08-01","conditions":["Hemodynamics"],"enrollment":99,"completionDate":"2026-07-30"},{"nctId":"NCT06425627","phase":"NA","title":"Spinal Versus General Anesthesia on Postoperative Pulmonary Complications","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-06-12","conditions":["Pulmonary Complication","Anesthesia","Hip Fractures"],"enrollment":40,"completionDate":"2026-05-20"},{"nctId":"NCT07028177","phase":"","title":"Changes in Etomidate Dosage in Insomnia Patients Undergoing Digestive Endoscopy","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-06-12","conditions":["Insomnia","Digestive Endoscopy"],"enrollment":840,"completionDate":"2027-03-31"},{"nctId":"NCT06065137","phase":"NA","title":"Standardised Drug Provocation Testing in Perioperative Hypersensitivity","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2023-10-23","conditions":["Allergic Reaction","Hypersensitivity","Perioperative Complication","Anaphylaxis","Anaphylactic Reaction","Immediate Hypersensitivity","Hypersensitivity, Drug"],"enrollment":50,"completionDate":"2025-06-30"},{"nctId":"NCT04934683","phase":"PHASE4","title":"The GUARDIAN Trial - Induction Agent Sub-Study","status":"ENROLLING_BY_INVITATION","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-07-25","conditions":["Major Surgery"],"enrollment":6254,"completionDate":"2027-04-25"},{"nctId":"NCT04828226","phase":"PHASE4","title":"Clonidine to Prevent Delirium After Electroconvulsive Therapy.","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-04-27","conditions":["Major Depressive Disorder","Catatonia","Bipolar Disorder","Delirium Postseizure"],"enrollment":130,"completionDate":"2026-07-31"},{"nctId":"NCT07079176","phase":"NA","title":"Etomidate Combined With Propofol Versus Propofol for Sedation in High-Altitude Patients During Gastroscopy: a Randomized Multicenter Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-08-01","conditions":["Gastrointestinal Endoscopy"],"enrollment":732,"completionDate":"2028-04-30"},{"nctId":"NCT07062601","phase":"NA","title":"Etomidate and Esketamine on Postoperative Pain After Tonsillectomy Undergoing Children","status":"NOT_YET_RECRUITING","sponsor":"Anqing Municipal Hospital","startDate":"2025-07-10","conditions":["Etomidate","Esketamine","Tonsillectomy","Children"],"enrollment":64,"completionDate":"2025-11-15"},{"nctId":"NCT07064434","phase":"NA","title":"Sacral Canal Block for Hip Replacement the Efficacy and Safety of Controlled Intraoperative Hypotension","status":"RECRUITING","sponsor":"General Hospital of Ningxia Medical University","startDate":"2024-11-01","conditions":["Postoperative Pain"],"enrollment":80,"completionDate":"2025-10-30"},{"nctId":"NCT05810363","phase":"NA","title":"The Safety of Etomidate - Propofol Mixture vs Propofol in Total Intravenous Anesthesia During Abdominal Surgery","status":"COMPLETED","sponsor":"Ailin Luo","startDate":"2023-06-16","conditions":["Etomidate","Hypotension"],"enrollment":468,"completionDate":"2024-10-30"},{"nctId":"NCT06179485","phase":"","title":"Effect of Ketamine and Etomidate During RSI on Long Term Outcomes","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-06","conditions":["Post-Traumatic Stress Disorder","Acute Respiratory Failure"],"enrollment":1756,"completionDate":"2028-03"},{"nctId":"NCT06953128","phase":"NA","title":"General Versus Regional Anesthesia in Peripheral Arterial Surgery","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2025-07-01","conditions":["Postoperative Complications","Cardiovascular Diseases"],"enrollment":594,"completionDate":"2028-06-30"},{"nctId":"NCT07019246","phase":"NA","title":"Safety of Etomidate-propofol Mixture vs. Propofol for Total Intravenous Anesthesia in Elderly Patients Undergoing Abdominal Surgery","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-02-01","conditions":["Etomidate Combined With Propofol","Hypertension"],"enrollment":166,"completionDate":"2026-06-05"},{"nctId":"NCT07012902","phase":"EARLY_PHASE1","title":"Relationship Between Remimazolam and Etomidate in Induction of General Anesthesia","status":"NOT_YET_RECRUITING","sponsor":"Second Hospital of Shanxi Medical University","startDate":"2025-06-12","conditions":["Induction Anesthesia","Drug Interactions"],"enrollment":125,"completionDate":"2025-07-19"},{"nctId":"NCT05688943","phase":"NA","title":"Comparative Analysis of Spinal Anesthesia Versus General Anesthesia for vNOTES","status":"ENROLLING_BY_INVITATION","sponsor":"University of Kansas Medical Center","startDate":"2023-03-01","conditions":["Anesthesia","Tubal Ligation"],"enrollment":20,"completionDate":"2026-07-15"},{"nctId":"NCT04940689","phase":"PHASE3","title":"Opioid-Free Anesthesia in Cardiac Surgery","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2021-07-22","conditions":["Anesthesia"],"enrollment":268,"completionDate":"2024-08-28"},{"nctId":"NCT06682546","phase":"PHASE2","title":"A Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride in Gastroscopy/Colonoscopy","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2024-11-15","conditions":["Gastroscopy","Colonoscopy"],"enrollment":78,"completionDate":"2024-12-27"},{"nctId":"NCT06976996","phase":"NA","title":"Efficacy of Esketamine Combined With Different General Anesthetics on Quality of Postoperative Recovery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2025-03-16","conditions":["Quality of Postoperative Recovery"],"enrollment":190,"completionDate":"2025-12-15"},{"nctId":"NCT00248729","phase":"PHASE2","title":"Effectiveness and Safety Study of Etomidate Versus Midazolam to Help Place a Breathing Tube Outside of the Hospital.","status":"COMPLETED","sponsor":"St. Luke's Hospital, Pennsylvania","startDate":"2002-10","conditions":["Respiratory Failure"],"enrollment":0,"completionDate":"2005-11"},{"nctId":"NCT06250374","phase":"NA","title":"Assessment of the Cerebral Perfusion During the Period of Deep Hypothermia at 18°C in Patient Undergoing Pulmonary Endarterectomy Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2023-08-24","conditions":["Hypothermia","Cerebral Perfusion","Transcranial Doppler Ultrasound","Pulmonary Hypertension"],"enrollment":45,"completionDate":"2025-05-24"},{"nctId":"NCT06858852","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride for Sedation/Anesthesia During Gastroscopy/Colonoscopy","status":"NOT_YET_RECRUITING","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2025-03","conditions":["Gastroscopy","Colonoscopy"],"enrollment":270,"completionDate":"2025-12"},{"nctId":"NCT05259787","phase":"PHASE4","title":"EP Intravenous Anesthesia in Hysteroscopy","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2022-09-28","conditions":["Anesthesia"],"enrollment":366,"completionDate":"2023-12-30"},{"nctId":"NCT06822166","phase":"PHASE1","title":"Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-12-04","conditions":["Interaction Drug Food"],"enrollment":68,"completionDate":"2024-01-23"},{"nctId":"NCT06822153","phase":"PHASE1","title":"Clinical Trial of the Effect of Methoxyethyl Etomidate Hydrochloride on the QT Interval of the Heart","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-11-09","conditions":["QT Interval, Variation in"],"enrollment":18,"completionDate":"2023-11-21"},{"nctId":"NCT06822114","phase":"PHASE1","title":"Substance Balance Trial of Methoxyethyl Etomidate Hydrochloride","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-07-17","conditions":["Pharmacokinetics"],"enrollment":6,"completionDate":"2023-07-31"},{"nctId":"NCT06616142","phase":"PHASE1,PHASE2","title":"Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-11-06","conditions":["Primary Aldosteronism"],"enrollment":12,"completionDate":"2027-05"},{"nctId":"NCT06764147","phase":"PHASE1","title":"Safety and Pharmacokinetics/ Pharmacodynamics of Methoxyethyl Etomidate Hydrochloride in Healthy Elderly Subjects","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-12-25","conditions":["Healthy Elderly Subjects"],"enrollment":16,"completionDate":"2024-02-02"},{"nctId":"NCT06747520","phase":"PHASE1","title":"Phase 1 Renal Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-11-30","conditions":["Renal Insufficiency"],"enrollment":24,"completionDate":"2024-02-28"},{"nctId":"NCT05407870","phase":"NA","title":"Efficacy and Safety of Etomidate Sedation in Gastric Endoscopic Submucosal Dissection","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2022-06-09","conditions":["Sedation Complication","Endoscopic Submucosal Dissection","Esophagogastroduodenoscopy"],"enrollment":138,"completionDate":"2022-11-24"},{"nctId":"NCT06664138","phase":"PHASE4","title":"Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment","status":"COMPLETED","sponsor":"Yeongseok Yun","startDate":"2023-04-28","conditions":["Schizophenia Disorder","Major Depression Disorders","Schizoaffective Disorder","Bipolar"],"enrollment":30,"completionDate":"2024-01-31"},{"nctId":"NCT06395961","phase":"NA","title":"Effect of New High Ankle Block on Wound Healing After the Operation of Debridement of Diabetes Foot","status":"ENROLLING_BY_INVITATION","sponsor":"Xuzhou Central Hospital","startDate":"2023-08-02","conditions":["Wound Heal","Diabetic Foot Ulcer"],"enrollment":70,"completionDate":"2025-06-15"},{"nctId":"NCT06608810","phase":"NA","title":"The Application of Pectoral Nerve II(PECS II)block in Breast Fibroadenoma Resection Surgery","status":"COMPLETED","sponsor":"Inner Mongolia Baogang Hospital","startDate":"2023-07-30","conditions":["Breast Neoplasms"],"enrollment":90,"completionDate":"2024-06-01"},{"nctId":"NCT05993390","phase":"NA","title":"Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-01-11","conditions":["Neuromuscular Blockade","Critical Illness","Neurologic Findings"],"enrollment":30,"completionDate":"2025-08-30"},{"nctId":"NCT05223907","phase":"PHASE4","title":"Safety and Efficacy of Maintenance of Etomidate in General Anesthesia","status":"COMPLETED","sponsor":"Henan Provincial People's Hospital","startDate":"2021-05-01","conditions":["General Anesthesia"],"enrollment":1080,"completionDate":"2022-12-31"},{"nctId":"NCT05888389","phase":"NA","title":"Nerve Block Anesthesia Combined With Sedative Anesthesia Versus General Anesthesia in Surgery for CSDH","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-04-01","conditions":["Chronic Subdural Hematoma","Anesthesia"],"enrollment":190,"completionDate":"2025-12-31"},{"nctId":"NCT06330038","phase":"PHASE4","title":"Anesthesia and Non-small Cell Lung Cancer Recurrence","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2024-05-01","conditions":["Non-small Cell Lung Cancer","Surgery","Anesthesia"],"enrollment":5384,"completionDate":"2028-12-31"},{"nctId":"NCT05748665","phase":"NA","title":"Effect of Remimazolam on the Recovery Quality After Day Surgery","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2023-08-14","conditions":["Elderly Patients","Ambulatory Surgery"],"enrollment":118,"completionDate":"2024-01-26"},{"nctId":"NCT04291521","phase":"","title":"Prospective Study of Induction Medications Used in the Trauma RSI","status":"NOT_YET_RECRUITING","sponsor":"University of Southern California","startDate":"2026-01-01","conditions":["Trauma","Rapid Sequence Intubation"],"enrollment":7000,"completionDate":"2028-07-30"},{"nctId":"NCT05899127","phase":"PHASE4","title":"Relationship Between Lidocaine and Serum Orphanin FQ (N/OFQ)","status":"UNKNOWN","sponsor":"Second Hospital of Shanxi Medical University","startDate":"2023-07-22","conditions":["Stress Reaction"],"enrollment":80,"completionDate":"2024-07-31"},{"nctId":"NCT06203431","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Methoxyetomidate Hydrochloride for Injection (ET-26) for the Induction of General Anesthesia in Elective Surgery Subjects","status":"UNKNOWN","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-10-11","conditions":["Anesthesia Induction"],"enrollment":270,"completionDate":"2024-06-30"},{"nctId":"NCT06068764","phase":"PHASE4","title":"Etomidate Versus Propofol in CABG Surgery","status":"RECRUITING","sponsor":"Hartford Hospital","startDate":"2023-12-05","conditions":["Coronary Artery Disease"],"enrollment":300,"completionDate":"2026-08"},{"nctId":"NCT06176716","phase":"PHASE1","title":"Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride","status":"UNKNOWN","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-12-06","conditions":["Hepatic Insufficiency"],"enrollment":24,"completionDate":"2024-04-30"},{"nctId":"NCT04281706","phase":"","title":"Impact of Etomidate vs. Propofol on Infectious Complications Post Cardiac Surgery","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2019-10-15","conditions":["Postoperative Complications"],"enrollment":1495,"completionDate":"2021-01-01"},{"nctId":"NCT05103696","phase":"NA","title":"A Comparative Study of Rimazolam and Propofol Combined With Etomidate in Gastroenteroscopy in Elderly Patients","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2021-10-01","conditions":["Elderly Patients","Gastrointestinal Endoscopy","Remimazolam Besylate","Etomidate Combined With Propofol"],"enrollment":120,"completionDate":"2023-03-30"},{"nctId":"NCT02453373","phase":"NA","title":"Helping Stroke Patients With ThermoSuit Cooling","status":"TERMINATED","sponsor":"Life Recovery Systems","startDate":"2017-01-25","conditions":["Stroke","Brain Ischemia"],"enrollment":14,"completionDate":"2023-06-02"},{"nctId":"NCT02822144","phase":"PHASE3","title":"General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2016-09-29","conditions":["Stroke"],"enrollment":351,"completionDate":"2020-08"},{"nctId":"NCT05862753","phase":"NA","title":"Duration and Depth of Anesthesia Induced by a Bolus of Etomidate","status":"COMPLETED","sponsor":"Erasme University Hospital","startDate":"2022-01-11","conditions":["Anesthesia"],"enrollment":18,"completionDate":"2022-04-20"},{"nctId":"NCT05754762","phase":"NA","title":"Median Effective Dose of Remifentanil for the Prevention of Myoclonus Induced by Etomidate Injection","status":"UNKNOWN","sponsor":"Yangzhou University","startDate":"2023-03-01","conditions":["Etomidate","Myoclonus"],"enrollment":70,"completionDate":"2023-07-01"},{"nctId":"NCT05619848","phase":"EARLY_PHASE1","title":"Effect of Paravertebral Muscle Fat Infiltration on Rocuronium Use in Lumbar Surgery","status":"COMPLETED","sponsor":"Zheng Guo","startDate":"2022-10-25","conditions":["Spinal Stenosis Lumbar"],"enrollment":87,"completionDate":"2022-12-30"},{"nctId":"NCT05624424","phase":"PHASE4","title":"Effect of Rematazolam Besylate, Propofol, and Sevoflurane Perioperative Sedation on Incidence of Emergence Agitation and Hemodynamics in Patients Undergoing Laparoscopic Abdominal Surgery","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2022-11-15","conditions":["Emergence Agitation","Remimazolam Besylate","Perioperative Sedation","Laparoscopic Abdominal Surgery","Anesthesia, General"],"enrollment":1317,"completionDate":"2023-10-31"},{"nctId":"NCT03585452","phase":"NA","title":"Effects of Dexmedetomidine on Cognitive Outcome and Brain Injury Markers","status":"COMPLETED","sponsor":"Michał Kowalczyk","startDate":"2018-08-01","conditions":["Cognitive Dysfunction"],"enrollment":23,"completionDate":"2019-03-31"},{"nctId":"NCT03852797","phase":"NA","title":"Spontaneous and Oxytocin-induced Contractility After Exposure to Intravenous Anesthetic Agents: an In-vitro Study in Human Myometrium","status":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2019-03-28","conditions":["Postpartum Hemorrhage"],"enrollment":33,"completionDate":"2022-01-19"},{"nctId":"NCT04316910","phase":"","title":"Characterisation of Gut Microbiota in Patients Undergoing Gastrointestinal Surgery With Postoperative Delirium (GIM-POD)","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2023-07-19","conditions":["Postoperative Delirium","Gut Microbiota"],"enrollment":30,"completionDate":"2024-09-30"},{"nctId":"NCT05520645","phase":"NA","title":"Etomidate Induction in Hysteroscopic Surgery","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-08-25","conditions":["Etomidate Induced Dose","Hysteroscopic Surgery"],"enrollment":200,"completionDate":"2023-12-30"},{"nctId":"NCT04369014","phase":"NA","title":"Effect of Etomidate and Propofol on Electroencephalography","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2022-02-28","conditions":["General Anesthesia"],"enrollment":68,"completionDate":"2023-02-28"},{"nctId":"NCT04120870","phase":"NA","title":"Comparison of Ketamine and Etomidate During Rapid Sequence Intubation in Trauma Patients","status":"TERMINATED","sponsor":"Ajou University School of Medicine","startDate":"2019-10-01","conditions":["Trauma","Shock, Traumatic"],"enrollment":10,"completionDate":"2021-12-30"},{"nctId":"NCT04527757","phase":"","title":"Duration of Anaesthesia Induction in Paediatric Patients: Prospective Observational Trial","status":"COMPLETED","sponsor":"Brno University Hospital","startDate":"2020-10-01","conditions":["Anaesthesia Induction"],"enrollment":1000,"completionDate":"2022-02-28"},{"nctId":"NCT02643381","phase":"PHASE4","title":"Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-06-06","conditions":["Cardiopulmonary Arrest","Respiratory Arrest"],"enrollment":801,"completionDate":"2020-12-01"},{"nctId":"NCT03545503","phase":"PHASE4","title":"Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation","status":"COMPLETED","sponsor":"South East Area Health Education Center, Wilmington, NC","startDate":"2018-01-01","conditions":["Intubation Complication"],"enrollment":428,"completionDate":"2019-09-01"},{"nctId":"NCT04865614","phase":"","title":"Comparison Between Inhalation and Intravenous Induction of Anaesthesia During Interventional Mitral Valve Repair","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2019-04-01","conditions":["Blood Pressure","Hypotension Drug-Induced"],"enrollment":57,"completionDate":"2020-12-01"},{"nctId":"NCT04934410","phase":"","title":"Induction Agent and Incidence of Hypotension in Heart Failure Patients Undergoing LVAD-Implantation","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2021-11-01","conditions":["Blood Pressure, Low"],"enrollment":50,"completionDate":"2022-12-31"},{"nctId":"NCT04873479","phase":"NA","title":"Effect of S-ketamine Anesthetic on Inflammatory Response in Septic Patients Undergoing Abdominal Surgery","status":"UNKNOWN","sponsor":"Tianjin Nankai Hospital","startDate":"2021-05-10","conditions":["Sepsis","Acute Lung Injury"],"enrollment":50,"completionDate":"2023-10-30"},{"nctId":"NCT02761330","phase":"NA","title":"Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04","conditions":["Depression","Delirium","Seizures","Cognitive Disorders"],"enrollment":17,"completionDate":"2019-09-11"},{"nctId":"NCT04921046","phase":"PHASE4","title":"Effect of Pretreatment of Lignocaine Versus Midazolam in Prevention of Etomidate Induced Myoclonus.","status":"COMPLETED","sponsor":"Rawalpindi Medical College","startDate":"2015-01-01","conditions":["Myoclonic Jerk"],"enrollment":224,"completionDate":"2015-06-30"},{"nctId":"NCT04866498","phase":"","title":"Pharmacotherapy Personalization of Cancer Patients","status":"COMPLETED","sponsor":"Poznan University of Medical Sciences","startDate":"2016-07-01","conditions":["Head and Neck Neoplasms","Oncologic Patients"],"enrollment":22,"completionDate":"2021-03-31"},{"nctId":"NCT04857450","phase":"NA","title":"Anesthesia for Upper Endoscopy and Colonoscopy in Cardiac Patients With Acute Anemia","status":"UNKNOWN","sponsor":"King Saud University","startDate":"2020-11-20","conditions":["Anemia","Cardiomyopathies","Pulmonary Hypertension"],"enrollment":60,"completionDate":"2021-12-20"},{"nctId":"NCT04788732","phase":"","title":"Heart Rate Variability to Quantify General Anesthesia Depth","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2021-01-04","conditions":["Anesthesia Awareness"],"enrollment":200,"completionDate":"2022-08-30"},{"nctId":"NCT03820388","phase":"PHASE4","title":"Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2017-12-01","conditions":["Surgery"],"enrollment":75,"completionDate":"2018-07-13"},{"nctId":"NCT02910206","phase":"NA","title":"Etomidate to Improve Outcome in Elderly Patients","status":"COMPLETED","sponsor":"Zhihong LU","startDate":"2017-08-15","conditions":["Postoperative Complications"],"enrollment":1917,"completionDate":"2020-11-20"},{"nctId":"NCT03542903","phase":"NA","title":"ECT in Ultra-resistant Schizophrenia","status":"UNKNOWN","sponsor":"Centre Hospitalier du Rouvray","startDate":"2018-07-04","conditions":["Schizophrenia","Electroconvulsive Therapy"],"enrollment":64,"completionDate":"2023-10-04"},{"nctId":"NCT02105415","phase":"PHASE2,PHASE3","title":"Ketamine / Propofol Admixture \"Ketofol\" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-04","conditions":["Critical Illness"],"enrollment":160,"completionDate":"2018-08-01"},{"nctId":"NCT04413422","phase":"","title":"Study on General Population of the Effect on Airway Protection of Drugs Used During Induction of General Anesthesia","status":"COMPLETED","sponsor":"Hospital San Carlos, Madrid","startDate":"2017-01-10","conditions":["Aspiration"],"enrollment":20,"completionDate":"2019-07-18"},{"nctId":"NCT03188029","phase":"NA","title":"Cortisol Level After Repeated Doses of Etomidate","status":"COMPLETED","sponsor":"University Tunis El Manar","startDate":"2017-10-03","conditions":["Adrenocortical Abnormality"],"enrollment":30,"completionDate":"2018-12-31"},{"nctId":"NCT03625076","phase":"PHASE4","title":"IAL vs PS for Anterior Shoulder Dislocations","status":"UNKNOWN","sponsor":"Kendall Healthcare Group, Ltd.","startDate":"2018-06-01","conditions":["Shoulder Dislocation"],"enrollment":70,"completionDate":"2020-06-01"},{"nctId":"NCT04054063","phase":"PHASE1","title":"A Study Evaluating Safety, Pharmacodynamics and Pharmacokinetics of HSK3486 and Etomidate for Induction of Anesthesia in Healthy Male Subjects","status":"COMPLETED","sponsor":"Sichuan Haisco Pharmaceutical Group Co., Ltd","startDate":"2016-11-30","conditions":["General Anesthetic","Sedation"],"enrollment":25,"completionDate":"2017-06-28"},{"nctId":"NCT01823328","phase":"PHASE4","title":"Ketamine Versus Etomidate for Rapid Sequence Intubation","status":"COMPLETED","sponsor":"Hennepin Healthcare Research Institute","startDate":"2013-09","conditions":["Airway Control","Anesthesia","Intubation","Complication"],"enrollment":143,"completionDate":"2015-10"},{"nctId":"NCT03855267","phase":"NA","title":"Etomidate/Propofol Mixture or Propofol Monotherapy Use in Patients Undergoing General Anesthesia","status":"UNKNOWN","sponsor":"Guolin Wang","startDate":"2019-01-01","conditions":["Etomidate is Mixed With Propofol"],"enrollment":200,"completionDate":"2019-12-01"},{"nctId":"NCT02500225","phase":"PHASE4","title":"Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy","status":"COMPLETED","sponsor":"Inonu University","startDate":"2017-01","conditions":["Anesthesia","ECT"],"enrollment":25,"completionDate":"2017-02"},{"nctId":"NCT02066077","phase":"NA","title":"The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2013-01-01","conditions":["Major Depressive Disorder"],"enrollment":280,"completionDate":"2017-12-31"},{"nctId":"NCT01566838","phase":"NA","title":"Continuous Subpleural Infusion of Bupivacaine","status":"COMPLETED","sponsor":"Inova Health Care Services","startDate":"2012-10","conditions":["Postoperative Pain"],"enrollment":83,"completionDate":"2015-12"},{"nctId":"NCT03240055","phase":"NA","title":"The Effects of Spinal Anesthesia on ED50 and BIS50 of Etomidate for the Loss of Consciousness","status":"COMPLETED","sponsor":"General Hospital of Ningxia Medical University","startDate":"2017-06-01","conditions":["Dose-Response Relationship, Drug"],"enrollment":54,"completionDate":"2017-07-15"},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":["Valvular Heart Disease"],"enrollment":226,"completionDate":"2017-05"},{"nctId":"NCT00596050","phase":"PHASE4","title":"Ketamine Versus Etomidate for Procedural Sedation for Pediatric Orthopedic Reductions","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2006-08","conditions":["Conscious Sedation Failure During Procedure"],"enrollment":50,"completionDate":"2008-06"},{"nctId":"NCT03137628","phase":"","title":"Effect of General Anesthesia and Mechanical Ventilation on Plasma Metabolite in Patient With Colorectal Cancer Resection","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2017-03-20","conditions":["Metabolomics"],"enrollment":80,"completionDate":"2017-05-15"},{"nctId":"NCT03129009","phase":"NA","title":"Hemodynamics and Vital Organ Function in Intracerebral Hemorrhage","status":"UNKNOWN","sponsor":"Xuzhou Medical University","startDate":"2017-04-01","conditions":["Balanced Anesthesia","Intracerebral Hemorrhage","Total Intravenous Anesthesia"],"enrollment":90,"completionDate":"2018-06-01"},{"nctId":"NCT02924090","phase":"PHASE4","title":"Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression","status":"UNKNOWN","sponsor":"University of Manitoba","startDate":"2016-09","conditions":["Depression"],"enrollment":48,"completionDate":"2018-12"},{"nctId":"NCT02840006","phase":"PHASE4","title":"Spinal Anesthesia Associated With General Anesthesia in Coronary Artery Bypass","status":"COMPLETED","sponsor":"Daniel Gioielli de Castilho","startDate":"2014-09","conditions":["Myocardial Revascularization","Spinal Anesthesia","Postoperative Care","Fentanyl"],"enrollment":60,"completionDate":""},{"nctId":"NCT02807610","phase":"PHASE4","title":"Etomidate vs Propofol-Induction Characteristics","status":"COMPLETED","sponsor":"Maharashtra University of Health Sciences","startDate":"2011-03","conditions":["Hemodynamics","Side Effects"],"enrollment":100,"completionDate":"2013-04"},{"nctId":"NCT01474252","phase":"PHASE4","title":"Comparison of Intubation Duration Between Rapid Sequence Intubation (RSI) Technique and Non-RSI Technique","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2008-07","conditions":["Tracheal Intubation Morbidity"],"enrollment":224,"completionDate":"2013-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection, Solution","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"ETOMIDATE"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Etomidate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"ETOMIDATE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Etomidate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"etomidate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"AMIDATE(TM) ETOMIDATE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Amidate"},{"form":"SOLUTION","route":"INTRAVENOUS","productName":"Etomidate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147047","MMSL":"10178","NDDF":"001402","UNII":"Z22628B598","VUID":"4018743","CHEBI":"CHEBI:4910","VANDF":"4018743","INN_ID":"1926","RXNORM":"215216","UMLSCUI":"C0015131","chemblId":"CHEMBL681","ChEMBL_ID":"CHEMBL681","KEGG_DRUG":"D00548","DRUGBANK_ID":"DB00292","PDB_CHEM_ID":"V8D","PUBCHEM_CID":"667484","SNOMEDCT_US":"387218008","IUPHAR_LIGAND_ID":"5463","MESH_DESCRIPTOR_UI":"D005045"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1982-","companyName":"Pfizer","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"3.5 hours","clearance":"13.0 mL/min/kg","fractionUnbound":"0.23%","volumeOfDistribution":"2.7 L/kg"},"publicationCount":3136,"therapeuticAreas":["Pain"],"atcClassification":{"source":"DrugCentral","atcCode":"N01AX07","allCodes":["N01AX07"]},"biosimilarFilings":[],"originalDeveloper":"Hospira","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":10,"_genericFilersChecked":true,"genericManufacturerList":["Avet Lifesciences","Caplin","Eugia Pharma","Gland","Hikma","Luitpold","Mylan Labs Ltd","Ph Health","Rising","Zydus Pharms"],"status":"approved","companyName":"Hospira","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1982","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1982-09-07T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:05:14.072359+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}